Premium
PEGylated Anti‐MUC1 Aptamer‐Doxorubicin Complex for Targeted Drug Delivery to MCF7 Breast Cancer Cells
Author(s) -
Tan Lihan,
Neoh Koon Gee,
Kang EnTang,
Choe Woo Seok,
Su Xiaodi
Publication year - 2011
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201100173
Subject(s) - doxorubicin , targeted drug delivery , drug delivery , aptamer , cytotoxicity , muc1 , drug , cancer cell , cancer , chemistry , pharmacology , cancer research , breast cancer , medicine , chemotherapy , biology , microbiology and biotechnology , biochemistry , in vitro , organic chemistry
Targeted drug delivery is especially important in cancer treatment as many anti‐cancer drugs are non‐specific and highly toxic to both cancer and normal cells. The targeted drug delivery of DOX to the MUC1‐expressing breast cancer cell line (MCF7) was obtained using APT as a carrier. Modification of the APT‐DOX complex by PEG increases the survivability of the macrophage control (RAW 264.7) by about six‐fold as compared to free DOX treatment without significantly affecting the cytotoxicity toward the target cell line. Thus, PEG‐APT‐DOX is potentially a new therapeutic agent for targeted drug delivery to MUC1‐expressing cell lines.